Collagen hydrolysates as active substances that slow down aging

Collagen hydrolysate addresses telomere shortening by inhibiting its rate and activating telomerase, effectively slowing down cellular aging and treating age-related diseases.

JP2026182882APending Publication Date: 2026-11-19GELITA AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2026190938
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-10-09
Filing Date
2026-08-20
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing active substances have not effectively addressed the issue of telomere shortening, which is associated with biological aging, particularly in skin and other somatic cells, leading to conditions like wrinkles, loss of elasticity, and age-related diseases.

Method used

Collagen hydrolysate is used as an active substance to inhibit telomere shortening and activate telomerase, thereby slowing down cellular aging and potentially treating or preventing age-related diseases.

Benefits of technology

Collagen hydrolysate significantly reduces telomere shortening rates and increases telomerase activity in human fibroblasts, demonstrating potential anti-aging benefits and therapeutic effects on age-related conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026182882000001
    Figure 2026182882000001
  • Figure 2026182882000002
    Figure 2026182882000002
  • Figure 2026182882000003
    Figure 2026182882000003
Patent Text Reader

Abstract

The objective of this invention is to propose an effective active substance that slows down the aging of cells in the body of humans or animals. [Solution] According to the present invention, to achieve this objective, the use of collagen hydrolysate as the corresponding active substance is proposed. As will be described in detail below, cell studies have shown that collagen hydrolysate significantly inhibits telomere shortening and activates telomerase.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The present invention relates to a collagen hydrolyzate for use as an active substance for delaying the senescence of cells in the human or animal body. BACKGROUND ART

[0002] On the one hand, the biological senescence of the human or animal body is associated with the influence of the external environment and accumulates over the entire lifetime. However, apart from such environmental influences, at the level of individual cells of the body, there is also a general association between aging and the gradual shortening of telomeres over a lifetime. Telomeres are repetitive DNA segments at the ends of chromosomes that initially shorten each time a cell divides. This shortening may be partially compensated by the DNA synthase telomerase, and the activity of telomerase varies greatly depending on the cell type. When the length of telomeres falls below a specific value, no further cell division occurs.

[0003] Regarding the senescence process of an organism, that is, the lifespan of an organism, what is relevant as the telomere shortening rate is not the original length of telomeres, but can be defined, for example, as the average shortening of telomeres in base pairs per year (see K Whittemore et al. in PNAS 116 (2019) 15122-15127).

[0004] For some time, active substances that counteract telomere shortening have been sought in this order to delay the senescence of cells of the human or animal body, and thus of tissues, organs, and the entire body. Such considerations are particularly (but not exclusively) relevant to skin senescence.

[0005] Various plant extracts have already been proposed as corresponding active substances for delaying senescence, for example, plants of the genera Astragalus and Cimicifuga in WO 2005 / 044179 A2, or plants of the genera Dendropanax and Kappaphycus in WO 2018 / 139835 A1. SUMMARY OF THE INVENTION [Problems that the invention aims to solve]

[0006] The objective of this invention is to propose an effective active substance that slows down the aging of cells in the body of humans or animals. [Means for solving the problem]

[0007] According to the present invention, to achieve this objective, the use of collagen hydrolysate as the corresponding active substance is proposed. As will be described in detail below, cell studies have shown that collagen hydrolysate significantly inhibits telomere shortening and activates telomerase.

[0008] In particular, the present invention relates to the use of collagen hydrolysates to slow down skin aging. This typically manifests as the formation of wrinkles, loss of elasticity, and the formation of so-called melasma. In this case, the body cells affected by the action of collagen hydrolysates are fibroblasts.

[0009] Other types of somatic cells that can slow down aging within the scope of the present invention include other connective tissue cells such as osteoblasts and chondrocytes, as well as muscle cells, nervous system cells (neurons), and immune system cells.

[0010] According to a preferred embodiment of the present invention, the use of collagen hydrolysates is for non-therapeutic purposes, i.e., particularly cosmetic purposes. This takes into account the fact that biological aging of the body is a natural process and not a pathological condition requiring treatment in a medical sense. Nevertheless, slowing down aging can contribute to an improved quality of life.

[0011] According to a further aspect of the present invention, the use of collagen hydrolysates is therapeutic, for the prevention and / or treatment of age-related diseases. These types of diseases associated with telomere shortening include, in particular, atherosclerosis, chronic liver disease, inflammatory bowel disease, and certain diseases of the adrenal glands and spleen. Other diseases that develop cumulatively with age include osteoporosis, arthropathy, sarcopenia, and dementia such as Alzheimer's disease.

[0012] In use according to the present invention, collagen hydrolysates preferably counteract telomere shortening in body cells, and in particular reduce the rate of telomere shortening. As mentioned above, the rate of telomere shortening correlates with lifespan, at least when compared across different species. Cellular studies conducted in human fibroblasts clearly demonstrated the reduction in this rate by collagen hydrolysates. [Modes for carrying out the invention]

[0013] Within the scope of use according to this invention, collagen hydrolysates can activate telomerase, an enzyme found in body cells. This effect was also demonstrated in cell studies using human fibroblasts. However, telomerase activation is not necessarily the only mechanism for counteracting telomere shortening.

[0014] It is true that the positive physiological effects of collagen hydrolysates, particularly in relation to osteoporosis and joint diseases, have been known for a long time. However, since there has been no indication of interaction between collagen hydrolysates and telomeres, the activity observed within the scope of this invention is quite surprising.

[0015] Depending on whether the use of collagen hydrolysates is non-therapeutic or therapeutic, within the scope of this invention, collagen hydrolysates may be administered as a dietary supplement or as a pharmaceutical. In either case, collagen hydrolysates are products that pose no health risks and have no known adverse side effects.

[0016] Preferably, collagen hydrolysates are administered orally. It is known that the peptides in collagen hydrolysates, even those with relatively high molecular weights up to 10,000 Da, are reabsorbed in the intestines to some extent. Therefore, in principle, orally administered collagen hydrolysates have the potential to reach cells throughout the body as sites of action.

[0017] The actual dosage forms of collagen hydrolysates may be powder, solution, gel, tablet, or capsule.

[0018] The daily dose of collagen hydrolysate administered, especially when administered orally, is preferably about 0.5 to about 20 g, preferably about 2 to about 15 g, more preferably about 3 to about 10 g, and especially about 4 to about 8 g.

[0019] As the active substance according to the present invention, collagen hydrolysates typically have an average molecular weight of 500 to 15000 Da, preferably 1000 to 8000 Da, more preferably 1500 to 5000 Da, and most preferably 1800 to 2200 Da. In each case, the cited values ​​refer to the weight-average molecular weight, which can be determined in particular by gel permeation chromatography.

[0020] Preferably, collagen hydrolysates are produced by enzymatic hydrolysis of a collagen-containing starting material. For this hydrolysis, endopeptidases or exopeptidases, particularly those of microbial or plant origin, are used. By appropriately selecting the peptidase and hydrolysis conditions, it becomes possible to produce collagen hydrolysates within the desired molecular weight range.

[0021] Collagen-containing starting materials are typically selected from the skin or bones of vertebrates, preferably mammals or birds, particularly from the skin of cattle or pigs (bovine splits or pigskin). Alternatively, collagen-containing starting materials may be selected from the skin, bones, and / or scales of fish, particularly cold-water or warm-water fish.

[0022] However, collagen hydrolysates can also be obtained from invertebrates as starting materials and used within the scope of the present invention. For example, collagen hydrolysates can be produced from mollusks or jellyfish.

[0023] Collagen hydrolysates can be produced from these starting materials in a one-step process or via an intermediate stage of gelatin, in which case both type A gelatin and type B gelatin can be used.

[0024] Preferably, the collagen hydrolysate is produced by the sequential action of at least two endoproteases with different specificities, in particular at least two different metalloproteases and / or serine proteases, that is, proteases that cleave before and after specific amino acids in the amino acid sequence of the collagen molecule, respectively. Preferably, the metalloproteases and / or serine proteases are enzymes from the microorganisms Bacillus subtilis, Bacillus licheniformis, Bacillus amyloliquefaciens, Aspergillus oryzae and Aspergillus melleus.

[0025] As a result of selecting appropriate endoproteases, it is not only possible to obtain a specific molecular weight distribution of the collagen hydrolysate, but also to influence the type of amino acids at the termini of the peptides in the hydrolysate. In this regard, for example, it is preferred that at least 50% of the N-terminal amino acids of the collagen hydrolysate are hydrophobic amino acids, in particular alanine, leucine and isoleucine.

[0026] As an alternative to enzymatic hydrolysis, within the scope of the present invention, collagen hydrolysates may be produced by recombinant gene expression. In particular, by using natural collagen sequences of bovine or porcine origin and expressing them in genetically modified cells (yeast, bacteria, or plant cells, especially tobacco), it is possible to produce products that are substantially identical to the hydrolysis products of the corresponding raw materials containing collagen. In this case, it is possible to obtain a narrower or precisely defined molecular weight distribution.

[0027] According to a further embodiment of the present invention, the collagen hydrolysate is administered in combination with at least one further active substance that counteracts telomere shortening in the body's cells. In some circumstances, this type of combination can achieve even more pronounced effects.

[0028] The at least one further active substance that counteracts telomere shortening is preferably selected from plant extracts of plants of the genera Astragalus (tragacanth), Cimicifuga (bugbane), Dendropanax and Kappaphycus.

[0029] According to a further embodiment of the present invention, the collagen hydrolysate is administered in a composition that contains no further active substances other than the collagen hydrolysate. In particular, it may be provided that the administered composition consists substantially entirely of the collagen hydrolysate.

[0030] When collagen hydrolysate is not used as the sole active substance, according to further embodiments of the present invention, it can be combined with one or more further components (e.g., in dietary supplements or pharmaceuticals) having positive physiological effects. Such components are preferably selected from: vitamin C, B vitamins

[0031] Furthermore, the present invention relates to a method for slowing the aging of cells in the body of a human or animal, comprising administering a collagen hydrolysate to a human or animal. The advantages and preferred embodiments of this method have already been described in relation to the collagen hydrolysate according to the present invention.

[0032] The effectiveness of collagen hydrolysates in telomere shortening will be explained in more detail with reference to the following examples. [Examples]

[0033] The following in vitro studies of human fibroblasts regarding the effects of collagen hydrolysates on telomere length and telomerase activity were conducted by Life Length in Madrid, Spain.

[0034] 1. The effect of collagen hydrolysates on telomere length 1.1 Cell culture All tests were performed in cell cultures of adult human fibroblasts. Inoculation was performed in 1 cm³ of high-glucose DMEM (Dulbeccoo's Eagle agar) supplemented with 10% fetal bovine serum, 100 units / ml penicillin, and 1,000 units / ml streptomycin. 2 Each case was performed with 2,000 cells. The culture medium was changed every 2-3 days, and the cells were subculturised every 4-5 days at a concentration of 70-80%.

[0035] In parallel with cell culture under standard conditions, cell culture was also tested under oxidative conditions, in which case the culture medium described above contained an additional 10 μM of H2O2.

[0036] 1.2 Hydrolyzed Collagen The collagen hydrolysate (KH) used in the test is marketed by the applicant under the name VERSIOL®. It is produced by enzymatic hydrolysis from type A gelatin of pigskin and has an average molecular weight of approximately 2000 Da.

[0037] The effects of collagen hydrolysate were tested at a wide range of concentrations. For this purpose, in each case, cell cultures were grown with 0.01 mg / ml, 0.1 mg / ml, 1 mg / ml, or 10 mg / ml of collagen hydrolysate added to the culture medium (under both standard and oxidized conditions). Collagen hydrolysate was not added to each control batch.

[0038] 1.3 Doubling of the population Cell cultures were grown for 8 weeks, and population doubling (PD) for each passage was determined weekly.

[0039] The cumulative PD values ​​for standard and oxidative conditions are shown in the table below.

[0040] [Table 1]

[0041] [Table 2]

[0042] As expected, population doubling under oxidative conditions was consistently lower than under standard conditions. In contrast, the presence of collagen hydrolysates did not significantly affect PD, meaning that cell proliferation itself was not affected by collagen hydrolysates.

[0043] 1.4 Determination of telomere length and shortening rate Telomere length is determined by in-situ fluorescence hybridization (FISH). For this purpose, a fluorescently labeled peptide nucleic acid probe hybridized with three repeating telomere sequences is used. The fluorescence intensity of a particular telomere is proportional to its length, and quantification is performed using control cells with known telomere lengths.

[0044] In all cell cultures tested, telomere lengths were determined at 4 and 8 weeks, and in the control batch, they were determined at the start of culture (week 0). Cells were fixed and lysed using pepsin, with five cell lysations performed at each time point and for each cell culture. DNA was stained with 4',6-diamidino-2-phenylindole (DAPI), and telomere hybridization was performed using probes.

[0045] Next, fluorescence microscopy was used to locate DAPI-stained cell nuclei, quantify the fluorescence of hybridized telomeres, and evaluate 15 different image sections batch by batch (cell lysis). Telomere length and distribution were calculated using appropriate software and statistically analyzed using Student's t-test.

[0046] 1.5 Results 1.5.1 Telomere Length The median telomere length, the 20th percentile (both in kilobase pairs, kbp), and the percentage of "short telomeres" (<3 kbp) were calculated for each cell culture at 4 and 8 weeks from data obtained by fluorescence microscopy. The results are shown in the table below. The p-values ​​obtained by t-tests comparing each sample to the corresponding sample in a control batch without collagen hydrolysate are also shown for each case. The difference from the control batch is statistically significant if the value is p<0.05. These values ​​are shown in bold.

[0047] [Table 3]

[0048] [Table 4]

[0049] These data demonstrate a significant effect of collagen hydrolysates on telomere length after fibroblasts have been cultured for at least 8 weeks. This effect applies to all concentrations tested, both under standard conditions and in the presence of H2O2.

[0050] 1.5.2 Telomere shortening rate In calculating the telomere shortening rate, the telomere length at 4 and 8 weeks after each cell culture was subtracted from the telomere length at the start of the culture, and this result was divided by the respective PD values ​​(see Section 1.3). Therefore, the rate represents the average telomere shortening per population doubling.

[0051] The results are shown in the table below. Here again, statistical significance is observed when compared to the control batch, which has a p-value of less than 0.05.

[0052] [Table 5]

[0053] [Table 6]

[0054] These data demonstrate a significant effect of collagen hydrolysates on telomere shortening rates, at least after 8 weeks of fibroblast culture. This effect applies to all concentrations tested, both under standard conditions and in the presence of H2O2.

[0055] 2. Effects of collagen hydrolysates on telomerase activity 2.1 Cell culture This study was conducted using primary cultures of adult human fibroblasts. The culture medium was high-glucose DMEM (Dulbeccoo's modified Eagle agar) supplemented with 10% fetal bovine serum, 100 units / ml penicillin, and 1,000 units / ml streptomycin.

[0056] Telomerase activity was measured at the start of culture and 24 hours later.

[0057] 2.2 Hydrolyzed Collagen The same collagen hydrolysate used to determine telomere length was used (see Section 1.2). This was added to the culture medium in amounts of 0.01 mg / ml, 0.1 mg / ml, 1 mg / ml, or 10 mg / ml. No collagen hydrolysate was added to the control batch.

[0058] 2.3 Measurement of telomerase activity The activity of the enzyme telomerase was determined by the TRAP (Telomere Repeat Amplification Protocol). For this purpose, cells were lysed and proteins were extracted. Oligonucleotide substrates were added, and these were extended by the extracted telomerase in a manner corresponding to native telomeres.

[0059] The telomerase reaction product was amplified using quantitative real-time PCR. The measured variable was the number of cycles after fluorescence first exceeded the threshold (Ct value). Calibration using HeLa cells of different concentrations allowed for the calculation of the relative telomerase activity (RTA) of the sample.

[0060] 2.4 Results The relative telomerase activity of fibroblasts at different KH concentrations at the start of culture and 24 hours later was measured three times for each case. The table below shows the mean, standard deviation (sd), and p-values ​​obtained by t-tests comparing each case to the control batch (no KH). A p-value of less than 0.05 indicates statistical significance.

[0061] [Table 7]

[0062] These data show that telomerase activity in fibroblasts increases with the addition of collagen hydrolysate at concentrations of 0.1, 1, or 10 mg / ml, but the increase is only significant at 0.1 mg / ml.

Claims

1. Collagen hydrolysates for use as active substances to slow the aging of cells in the body of humans or animals.

2. The collagen hydrolysate according to claim 1, wherein the cells of the body are fibroblasts.

3. The collagen hydrolysate according to claim 1 or 2, wherein the use is non-therapeutic, particularly cosmetic.

4. The collagen hydrolysate according to claim 1 or 2, wherein the use is a therapeutic use for preventing and / or treating age-related diseases.

5. The collagen hydrolysate according to any one of claims 1 to 4, wherein the collagen hydrolysate counteracts telomere shortening of body cells and, in particular, reduces the rate of telomere shortening.

6. The collagen hydrolysate according to claim 5, wherein the collagen hydrolysate activates telomerase, an enzyme in the cells of the body.

7. The collagen hydrolysate according to any one of claims 1 to 6, wherein the collagen hydrolysate is administered orally.

8. The collagen hydrolysate according to claim 7, wherein the collagen hydrolysate is administered in the form of a powder, solution, gel, tablet, or capsule.

9. The collagen hydrolysate according to any one of claims 1 to 8, wherein the collagen hydrolysate is administered in a daily dose of about 0.5 to about 20 g, preferably about 2 to about 15 g, more preferably about 3 to about 10 g, and particularly about 4 to about 8 g.

10. The collagen hydrolysate according to any one of claims 1 to 9, wherein the collagen hydrolysate has an average molecular weight of 500 to 15000 Da, preferably 1000 to 8000 Da, more preferably 1500 to 5000 Da, and most preferably 1800 to 2200 Da.

11. The collagen hydrolysate according to any one of claims 1 to 10, wherein the collagen hydrolysate is produced by enzymatic hydrolysis of a starting material containing collagen.

12. The collagen hydrolysate according to claim 11, wherein the collagen-containing starting material is selected from the skin or bone of a vertebrate, preferably a mammal, bird, or fish, and particularly from the skin of a cow or pig.

13. The collagen hydrolysate according to claim 11 or 12, wherein the collagen hydrolysate is produced by the sequential action of at least two endoproteases with different specificities, particularly at least two different metalloproteases and / or serine proteases.

14. The collagen hydrolysate according to claim 13, wherein the metalloproteinase and / or serine protease is selected from enzymes from the microorganisms Bacillus subtilis, Bacillus licheniformis, Bacillus amyloliquefaciens, Aspergillus oryzae, and Aspergillus melleus.

15. The collagen hydrolysate according to claim 14, wherein at least 50% of the N-terminal amino acids of the collagen hydrolysate are hydrophobic amino acids, particularly alanine, leucine, and isoleucine.

16. The collagen hydrolysate according to any one of claims 1 to 10, wherein the collagen hydrolysate is produced by recombinant gene expression.

17. The collagen hydrolysate according to any one of claims 1 to 16, wherein the collagen hydrolysate is administered in combination with at least one further active substance that counteracts telomere shortening of cells in the body.

18. The collagen hydrolysate according to claim 17, wherein the at least one further active substance is selected from plant extracts of plants of the genus Astralagus (tragacanth), Simisifuga (bagbein), Dendropanax, and Kappaficus.

19. The collagen hydrolysate according to any one of claims 1 to 16, wherein the collagen hydrolysate is to be administered in a composition that does not contain any further active substances other than the collagen hydrolysate.

20. The collagen hydrolysate according to claim 19, wherein the administered composition consists substantially entirely of collagen hydrolysates.